Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Year: 2022
Type: article
Abstract: Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients respond to ICIs, highlighting the need for superior immunotherapy. Herein, we report on a nanoparticle-based immunotherapy termed ARAC (Antigen Release Agent and Checkpoint Inhibitor) designed to enhance the efficacy of PD-L1 inhibitor. ARAC is a nanoparticle co-delivering PLK1 inhibitor (volasertib) and PD-L1 antibody. PLK1 is a key mitotic kinase that is overexpressed in various cancers including NSCLC and drives cancer growth. Inhibition of PLK1 selectively kills cancer cells and upregulates PD-L1 expression in surviving cancer cells thereby providing opportunity for ARAC targeted delivery in a feedforward manner. ARAC reduces effective doses of volasertib and PD-L1 antibody by 5-fold in a metastatic lung tumor model (LLC-JSP) and the effect is mainly mediated by CD8+ T cells. ARAC also shows efficacy in another lung tumor model (KLN-205), which does not respond to CTLA-4 and PD-1 inhibitor combination. This study highlights a rational combination strategy to augment existing therapies by utilizing our nanoparticle platform that can load multiple cargo types at once.
Source: Nature Communications
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,890
Funders: Oregon Health and Science University, University of Texas Southwestern Medical Center, National Institutes of Health, University of Texas MD Anderson Cancer Center, Knight Cancer Institute, Oregon Health and Science University, National Cancer Institute, National Center for Advancing Translational Sciences
Awards: Development of topical formulation of siRNA-nanoparticle for treating skin diseases, Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer, Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer, In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response
OpenAlex ID: W4286742004
